SPRB
Spruce·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SPRB
Spruce Biosciences, Inc.
A clinical late stage biopharmaceutical company focused on developing and commercializing new therapies for rare endocrine disorders
611 Gateway Boulevard, Suite 740, South San Francisco, California 94080
--
Spruce Biosciences, Inc., was originally incorporated as a limited liability company in Delaware in November 2014. The company is a late-stage biopharmaceutical company focused on developing and commercializing new therapies for rare endocrine diseases with unmet medical needs. The company is initially developing a wholly-owned product candidate, tildacerfont, as a potential first non-steroidal therapy to provide significantly improved disease control and reduced steroid burden for patients with typical congenital adrenal hyperplasia.
Company Financials
EPS
SPRB has released its 2025 Q3 earnings. EPS was reported at -14.58, versus the expected -12.31, missing expectations. The chart below visualizes how SPRB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
